XML 142 R98.htm IDEA: XBRL DOCUMENT v3.22.4
Principal changes in the scope of consolidation in 2022 - Summary of Provisional Purchase Price Allocation (Details) - Amunix Pharmaceuticals, Inc
€ in Millions
Feb. 08, 2022
EUR (€)
Disclosure of detailed information about business combination [line items]  
Other intangible assets € 493
Other current and non-current assets and liabilities (13)
Cash and cash equivalents 118
Net deferred tax position (81)
Net assets of Translate Bio 517
Goodwill 609
Purchase price € 1,126